rdf:type |
|
lifeskim:mentions |
umls-concept:C0020003,
umls-concept:C0030705,
umls-concept:C0035173,
umls-concept:C0253563,
umls-concept:C0302350,
umls-concept:C0587437,
umls-concept:C0809949,
umls-concept:C0948089,
umls-concept:C1522609,
umls-concept:C1540850,
umls-concept:C1554112
|
pubmed:issue |
2
|
pubmed:dateCreated |
2001-2-16
|
pubmed:abstractText |
We aimed to evaluate the benefits of the glycoprotein (GP) IIb/IIIa antagonist, eptifibatide, after patients with acute coronary syndromes (ACS) were admitted to hospitals that approach revascularization for ACS through early transfer to tertiary referral centers.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0735-1097
|
pubmed:author |
pubmed-author:BerdanL GLG,
pubmed-author:CaliffR MRM,
pubmed-author:CokkinosD VDV,
pubmed-author:GreenbaumA BAB,
pubmed-author:GuerciAA,
pubmed-author:HarringtonR ARA,
pubmed-author:HudsonM PMP,
pubmed-author:KatzE SES,
pubmed-author:LincoffA MAM,
pubmed-author:MacAulayC MCM,
pubmed-author:OhmanE MEM,
pubmed-author:SimoonsM LML,
pubmed-author:TopolE JEJ,
pubmed-author:WilcoxR GRG
|
pubmed:issnType |
Print
|
pubmed:volume |
37
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
492-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11216968-Aged,
pubmed-meshheading:11216968-Coronary Disease,
pubmed-meshheading:11216968-Female,
pubmed-meshheading:11216968-Hospitals, Community,
pubmed-meshheading:11216968-Humans,
pubmed-meshheading:11216968-Male,
pubmed-meshheading:11216968-Middle Aged,
pubmed-meshheading:11216968-Myocardial Infarction,
pubmed-meshheading:11216968-Myocardial Revascularization,
pubmed-meshheading:11216968-Patient Transfer,
pubmed-meshheading:11216968-Peptides,
pubmed-meshheading:11216968-Platelet Aggregation Inhibitors,
pubmed-meshheading:11216968-Referral and Consultation,
pubmed-meshheading:11216968-Survival Rate
|
pubmed:year |
2001
|
pubmed:articleTitle |
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.
|
pubmed:affiliation |
Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA. agreenb1@hfhs.org
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|